Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101671170 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-139X (Electronic) Linking ISSN: 23791381 NLM ISO Abbreviation: Tomography Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : Basel, Switzerland : MDPI
      Original Publication: Ann Arbor, Michigan : Grapho Publications LLC, [2015]-
    • Subject Terms:
      Pancreatic Neoplasms*/diagnostic imaging ; Pancreatic Neoplasms*/pathology ; Contrast Media* ; Tomography, X-Ray Computed*/methods; Humans ; Female ; Male ; Aged ; Middle Aged ; Pancreas/diagnostic imaging ; Pancreas/pathology ; Aged, 80 and over ; Retrospective Studies ; Radiography, Dual-Energy Scanned Projection/methods ; Adult ; Radiographic Image Enhancement/methods
    • Abstract:
      Background/Objectives : The usefulness of dual-energy computed tomography (DECT) for low absorption in the parenchymal phase and contrast effects in the delayed phase for pancreatic cancer is not clear. Therefore, the diagnostic capability of low-KeV images obtained using DECT for pancreatic cancer in the pancreatic parenchymal and delayed phases was evaluated quantitatively and qualitatively. Methods : Twenty-five patients with pancreatic cancer who underwent contrast-enhanced DECT were included. A total of 50 and 70 KeV CT images, classified as low-keV and conventional CT-equivalent images, were produced, respectively. The tumor-to-pancreas contrast (Hounsfield units [HU]) in the pancreatic parenchymal and delayed phases was calculated by subtracting the CT value of the pancreatic tumor from that of normal parenchyma. Results : The median tumor-to-pancreas contrast on 50 KeV CT in the pancreatic parenchymal phase (133 HU) was higher than that on conventional CT (68 HU) ( p < 0.001). The median tumor-to-pancreas contrast in the delayed phase was -28 HU for 50 KeV CT and -9 HU for conventional CT ( p = 0.545). For tumors < 20 mm, the tumor-to-pancreas contrast of 50 KeV CT (-39 HU) had a significantly clearer contrast effect than that of conventional CT (-16.5 HU), even in the delayed phase ( p = 0.034). Conclusions : These 50 KeV CT images may clarify the low-absorption areas of pancreatic cancer in the pancreatic parenchymal phase. A good contrast effect was observed in small pancreatic cancers on 50 KeV delayed-phase images, suggesting that DECT is useful for the visualization of early pancreatic cancer with a small tumor diameter.
    • References:
      Clin Gastroenterol Hepatol. 2018 Mar;16(3):318-327. (PMID: 29074447)
      Pancreas. 2022 Nov-Dec 01;51(10):1352-1358. (PMID: 37099778)
      Diagnostics (Basel). 2024 Mar 22;14(7):. (PMID: 38611587)
      Clin Radiol. 2013 Feb;68(2):148-54. (PMID: 22889459)
      Abdom Radiol (NY). 2017 Oct;42(10):2579-2586. (PMID: 28421243)
      Radiology. 2011 May;259(2):442-52. (PMID: 21406627)
      Dig Endosc. 2021 Jan;33(2):298-305. (PMID: 33098123)
      Abdom Radiol (NY). 2023 Aug;48(8):2596-2603. (PMID: 37210407)
      Ann Surg Oncol. 2009 Jul;16(7):1725-6. (PMID: 19396495)
      Abdom Radiol (NY). 2019 Feb;44(2):568-575. (PMID: 30155698)
      Eur Radiol. 2020 Jan;30(1):394-403. (PMID: 31312889)
      N Engl J Med. 2014 Sep 11;371(11):1039-49. (PMID: 25207767)
      Acad Radiol. 2011 Aug;18(8):991-9. (PMID: 21536464)
      J Comput Assist Tomogr. 2017 Jan;41(1):39-47. (PMID: 27560021)
      J Cancer Res Clin Oncol. 2014 Dec;140(12):2077-86. (PMID: 24916170)
      Phys Med Biol. 2020 Jun 01;65(10):105012. (PMID: 32187583)
      Eur J Radiol. 2023 Feb;159:110685. (PMID: 36603479)
      BMC Med. 2022 Mar 2;20(1):74. (PMID: 35232446)
      Radiographics. 2021 Mar-Apr;41(2):509-523. (PMID: 33606565)
      Pancreatology. 2018 Jan;18(1):61-67. (PMID: 29170051)
      CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
      Eur J Radiol. 2015 Nov;84(11):2052-8. (PMID: 26220917)
      Jpn J Radiol. 2013 Aug;31(8):521-9. (PMID: 23793776)
      Eur Radiol. 2023 Oct;33(10):6883-6891. (PMID: 37083741)
      Cancers (Basel). 2023 Jan 05;15(2):. (PMID: 36672301)
      Gastrointest Endosc. 2022 Apr;95(4):723-732.e7. (PMID: 34736932)
      J Comput Assist Tomogr. 2015 Nov-Dec;39(6):907-13. (PMID: 26295192)
      Lancet. 2011 Aug 13;378(9791):607-20. (PMID: 21620466)
      Abdom Imaging. 2015 Jun;40(5):1230-40. (PMID: 25331567)
      Eur Radiol. 2021 Sep;31(9):6898-6908. (PMID: 33744992)
      AJR Am J Roentgenol. 2021 Oct;217(4):888-897. (PMID: 33759561)
      J Gastroenterol. 2019 Jan;54(1):19-32. (PMID: 30406288)
      Endoscopy. 2023 Feb;55(2):140-149. (PMID: 35688454)
      Dig Endosc. 2020 Mar;32(3):399-408. (PMID: 31361926)
      Surg Oncol. 2015 Dec;24(4):322-8. (PMID: 26690821)
      Abdom Radiol (NY). 2024 May;49(5):1489-1501. (PMID: 38580790)
      Eur Radiol. 2019 Jul;29(7):3617-3625. (PMID: 30888484)
      Sci Rep. 2023 Aug 21;13(1):13628. (PMID: 37604973)
      CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786)
    • Contributed Indexing:
      Keywords: contrast; delayed phase; dual-energy computed tomography; pancreatic cancer
    • Accession Number:
      0 (Contrast Media)
    • Publication Date:
      Date Created: 20241025 Date Completed: 20241025 Latest Revision: 20241027
    • Publication Date:
      20241027
    • Accession Number:
      PMC11510840
    • Accession Number:
      10.3390/tomography10100117
    • Accession Number:
      39453034